title: HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy.
abstract: BACKGROUND
  The mucin MUC16 expresses the repeating peptide epitope CA125 that has been known for decades to be a well-validated cancer marker that is overexpressed on the cell surface of ovarian cancers and other malignant tumors. In spite of recent efforts to make mouse monoclonal antibodies to MUC16 to treat ovarian cancer, a human monoclonal antibody against this mucin has not been described. MUC16 interacts with mesothelin, a protein that mediates heterotypic cancer cell adhesion, indicating that MUC16 and mesothelin play an important role in the peritoneal implantation and metastasis of ovarian tumors. Therefore, a suitable candidate for therapeutic targeting of MUC16 would functionally block the interaction of MUC16 and mesothelin.
  
  
  RESULTS
  Here we report the generation of a novel immunoadhesin, HN125, against MUC16 that consists of a functional MUC16 binding domain of mesothelin (IAB) and the Fc portion of a human antibody IgG1. The yield for purified HN125 proteins is over 100 µg/mL of HEK-293 culture supernatant. We show that HN125 has high and specific affinity for MUC16-expressing cancer cells by flow cytometry and immunohistochemistry. HN125 has the ability to disrupt the heterotypic cancer cell adhesion mediated by the MUC16-mesothelin interaction. Moreover, it elicits strong antibody-dependent cell mediated cytotoxicity against MUC16-positive cancer cells in vitro.
  
  
  CONCLUSIONS
  This report describes a novel human immunotherapeutic agent highly specific for MUC16 with potential for treating ovarian cancer and other MUC16-expressing tumors. Because of its lower immunogenicity in patients, a fully human protein is the most desirable format for clinical applications. We believe that the methods developed here may apply to the generation of other tumor-targeting immunoadhesins when it is difficult to obtain a human monoclonal antibody to a given antigen for clinical applications. The resultant immunoadhesins can have advantages usually found in monoclonal antibodies such as ease of purification, high binding affinity and effector functions.
authors: 1. Antibody Therapy Unit, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA;
authors: Xinran
authors: X
authors: Xiang
authors: Mingqian
authors: M
authors: Feng
authors: Mildred
authors: M
authors: Felder
authors: Joseph P
authors: JP
authors: Connor
authors: Yan-Gao
authors: YG
authors: Man
authors: Manish S
authors: MS
authors: Patankar
authors: Mitchell
authors: M
authors: Ho
references: Mol Cancer. 2006 Oct 26;5(1):50
references: 17067392
references: J Clin Invest. 1981 Nov;68(5):1331-7
references: 7028788
references: J Biol Chem. 2009 Feb 6;284(6):3739-49
references: 19075018
references: J Biol Chem. 2004 Mar 5;279(10):9190-8
references: 14676194
references: Int J Cancer. 2011 May 1;128(9):2020-30
references: 20635390
references: Exp Eye Res. 2004 Mar;78(3):379-88
references: 15106916
references: Gynecol Oncol. 2005 Mar;96(3):902-5
references: 15721449
references: Gynecol Oncol. 2005 Dec;99(3):704-13
references: 16126266
references: Gynecol Oncol. 2009 Jun;113(3):384-90
references: 19232697
references: Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4509-18
references: 17898272
references: Biol Reprod. 2008 Jan;78(1):134-42
references: 17942799
references: J Cancer. 2011 Mar 01;2:123-31
references: 21479131
references: Eur J Cancer. 2008 Jan;44(1):46-53
references: 17945478
references: J Cancer. 2010 Oct 01;1:141-9
references: 20922056
references: J Immunother. 2008 Feb-Mar;31(2):207-14
references: 18481390
references: Mol Cancer. 2010 May 24;9:118
references: 20497550
references: Int J Biochem Cell Biol. 2007;39(10):1943-54
references: 17604678
references: Am J Obstet Gynecol. 2003 Jul;189(1):28-36
references: 12861134
references: Invest Ophthalmol Vis Sci. 2003 Jun;44(6):2487-95
references: 12766047
references: Nat Protoc. 2010 Apr;5(4):725-38
references: 20360767
references: Int J Gynecol Pathol. 1998 Jan;17(1):61-5
references: 9475194
references: Cancer. 1995 Apr 15;75(8):2147-52
references: 7697606
references: Toxicology. 2000 Apr 3;144(1-3):221-8
references: 10781891
references: PLoS One. 2011 Jan 31;6(1):e14640
references: 21305058
references: Immunology. 2007 Nov;122(3):418-29
references: 17617155
references: Cancer. 2003 Jul 1;98(1):66-73
references: 12833457
references: J Clin Oncol. 2007 Nov 20;25(33):5165-71
references: 18024863
references: Cancer Res. 2007 May 15;67(10):4924-32
references: 17510422
references: MAbs. 2011 Jan-Feb;3(1):76-99
references: 21051951
references: J Clin Oncol. 1992 Apr;10(4):529-35
references: 1548517
references: Am J Obstet Gynecol. 1991 Feb;164(2):669-74
references: 1992720
references: J Ovarian Res. 2010 Mar 29;3:8
references: 20350313
references: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references: 20610543
references: Cancer Lett. 2007 Mar 8;247(1):130-6
references: 16677756
references: J Virol. 2005 Jul;79(14):8828-34
references: 15994776
references: Ann Oncol. 2004 Jan;15(1):104-12
references: 14679128
references: Clin Cancer Res. 2005 May 15;11(10):3814-20
references: 15897581
references: Curr Opin Biotechnol. 2009 Dec;20(6):692-9
references: 19889530
references: J Cancer. 2010 Jul 13;1:93-7
references: 20842229
references: Gynecol Oncol. 2006 Aug;102(2):140-4
references: 16790264
references: J Virol. 2010 Mar;84(6):2955-62
references: 20042512
references: Biochim Biophys Acta. 2003 Jul 30;1638(3):257-66
references: 12878327
references: Exp Eye Res. 2010 Jun;90(6):655-63
references: 20223235
references: Clin Cancer Res. 2007 Mar 1;13(5):1571-5
references: 17332303
references: J Clin Oncol. 2004 Sep 1;22(17):3507-16
references: 15337799
references: Gynecol Oncol. 2004 Aug;94(2):340-51
references: 15297171